Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Depreciation & Amortization (CF) (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Depreciation & Amortization (CF) for 9 consecutive years, with $551000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) changed N/A to $551000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a N/A change, with the full-year FY2025 number at $2.0 million, up 1.51% from a year prior.
  • Depreciation & Amortization (CF) was $551000.0 for Q4 2025 at Soleno Therapeutics, up from $502000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $551000.0 in Q4 2025 to a low of $502000.0 in Q2 2025.